Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Daniel J. DeAngelo, MD, Harry P. Erba, MDPhD, Elie Traer, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Cecilia Arana-Yi, MD, William Blum, MD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 26.

https://doi.org/10.1182/blood-2018-99-112891

Published: 2018

Journal Articles

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Elie Traer, MD PhD, Eunice S. Wang, MD, Harry P. Erba, MD PhD, William Blum, MD, Cecilia Arana-Yi, MD, Callum M. Sloss, Kerry Culm-Merdek, Jeanette Towles, Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MD

Blood (2017) 130 (Supplement 1): 1312.

https://doi.org/10.1182/blood.V130.Suppl_1.1312.1312

Published: 2017

Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 2068.

https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068

Published: 2017

Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Blood (2017) 130 (Supplement 1): 725.

https://doi.org/10.1182/blood.V130.Suppl_1.725.725

Published: 2017

Journal Articles

Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors

Elie Traer, MD PhD, Brian J. Druker, MD, Jakki Martinez, Nathalie Javidi-Sharifi, Isabel English, BA, Anupriya Agarwal, PhD, Jennifer Dunlap, MD

Blood (2017) 130 (Supplement 1): 306.

https://doi.org/10.1182/blood.V130.Suppl_1.306.306

Published: 2017

Journal Articles

Cytokine-Mediated Inflammatory Pathways Promote Clonal Evolution and Disease Progression in Acute Myeloid Leukemia

Christopher O. Eden, BA, David K. Edwards, V, BA, BS, Christopher A. Eide, Elie Traer, MD, Jeffrey W. Tyner, Shannon K. McWeeney, Anupriya Agarwal

Blood (2016) 128 (22): 1688.

https://doi.org/10.1182/blood.V128.22.1688.1688

Published: 2016

Journal Articles

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Elie Traer, MD, Nathalie Javidi-Sharifi, Jacqueline Martinez, MS, Isabel English, Jennifer Dunlap, MD, Anupriya Agarwal, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker, MD

Blood (2016) 128 (22): 1080.

https://doi.org/10.1182/blood.V128.22.1080.1080

Published: 2016

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Stephen E Spurgeon, MD, Rachel Cook, MD MS, Elie Traer, MD, Uma Borate, MD, Richard T. Maziarz, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Tara Macey, PhD, Kristen Werth, Brian Junio, Cristina E. Tognon, Motomi Mori, PhD, Marc Loriaux, MD PhD

Blood (2016) 128 (22): 4051.

https://doi.org/10.1182/blood.V128.22.4051.4051

Published: 2016

Journal Articles

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples

Sacha L. Prashad, PhD, Leylah Drusbosky, PhD, Hassan Sibai, MD, Mark D. Minden, MD PhD, Stephen J. Western, Chris Biondi, MS, Reecha Shah, MS, Debra Liu, MS, Transon Nguyen, MS, Connor Warnock, BS, Pete Quinzio, BA, Matthew De Silva, BS, Elie Traer, MD, Christopher R. Cogle, MD, Aaron D. Schimmer, MD PhD, Diane Heiser, PhD

Blood (2016) 128 (22): 5206.

https://doi.org/10.1182/blood.V128.22.5206.5206

Published: 2016

Journal Articles

Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Vishesh Khanna, BS, Samantha L. Savage, Angela Rofelty, Isabel English, Hibery Ho, Motomi Mori, PhD, Elie Traer, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2016) 128 (22): 836.

https://doi.org/10.1182/blood.V128.22.836.836

Published: 2016

Journal Articles

FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors

Jacqueline Martinez, MS, Nathalie Javidi-Sharifi, Isabel English, Shelton A. Viola, MD, Danielle Jorgens, PhD, Brian J. Druker, MD, Elie Traer, MD PhD

Blood (2015) 126 (23): 2465.

https://doi.org/10.1182/blood.V126.23.2465.2465

Published: 2015

Journal Articles

Mutations Modifying Risk in NPM1+ AML

Jessica Leonard, MD, Jennifer Dunlap, MD, Tanaya L Neff, Andrea Warrick, Fei Yang, Richard D. Press, MD PhD, Brian J. Druker, MD, Elie Traer, MD, PhD

Blood (2015) 126 (23): 2592.

https://doi.org/10.1182/blood.V126.23.2592.2592

Published: 2015

Journal Articles

Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

Tyler Sweeney, Stephen E Spurgeon, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD, Hibery Ho, Elie Traer, MD PhD, Patrice Lee, PhD, David Chantry, PhD, Brian J. Druker, MD, Marc Loriaux, MD PhD

Blood (2015) 126 (23): 4439.

https://doi.org/10.1182/blood.V126.23.4439.4439

Published: 2015

Journal Articles

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

David K Edwards, V, B.A., B.S., Angela Rofelty, BS, Anupriya Agarwal, PhD, Stephen E Kurtz, PhD, Elie Traer, MD PhD, Patrice Lee, PhD, David Chantry, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 3824.

https://doi.org/10.1182/blood.V126.23.3824.3824

Published: 2015

Journal Articles

Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens

Stephen E Kurtz, PhD, Elie Traer, MD PhD, Jakki Martinez, Andrew Park, Jake Wagner, Ravi Pandya, PhD, William Bolosky, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 865.

https://doi.org/10.1182/blood.V126.23.865.865

Published: 2015

Journal Articles

The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia

Alyssa Carey, BS, Megan M Cleary, B.S., B.A., David K Edwards, V, B.A., B.S., Christopher A. Eide, Elie Traer, MD PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner, PhD, Grover C. Bagby, MD, Brian J. Druker, MD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 866.

https://doi.org/10.1182/blood.V126.23.866.866

Published: 2015

Journal Articles

Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic Cellular Growth and Disease Progression in Primary Human Cells and Murine Models of Acute Myeloid leukemia

Alyssa Carey, B.A., David Edwards, B.A., B.S., Christopher A. Eide, Elie Traer, MD, PhD, Jeffrey W. Tyner, Grover C. Bagby, MD MACP, Brian J. Druker, Anupriya Agarwal

Blood (2014) 124 (21): 702.

https://doi.org/10.1182/blood.V124.21.702.702

Published: 2014

Journal Articles

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 2541.

https://doi.org/10.1182/blood.V122.21.2541.2541

Published: 2013

Journal Articles

FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 3983.

https://doi.org/10.1182/blood.V122.21.3983.3983

Published: 2013

NARROW

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors

Cytokine-Mediated Inflammatory Pathways Promote Clonal Evolution and Disease Progression in Acute Myeloid Leukemia

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples

Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies

FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors

Mutations Modifying Risk in NPM1+ AML

Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens

The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia

Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic Cellular Growth and Disease Progression in Primary Human Cells and Murine Models of Acute Myeloid leukemia

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only